<DOC>
	<DOC>NCT03014635</DOC>
	<brief_summary>This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.</brief_summary>
	<brief_title>Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Provide written informed consent including authorization to release health information Moderate (2) or severe (3) glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity (IGAFWS) scale Moderate (2) or severe (3) glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity (PFWS) scale Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as LambertEaton syndrome and myasthenia gravis Active skin disease, infections or inflammation at the injection sites Plan to receive botulinum toxin type A anywhere in the face through the duration of the study History of allergy or sensitivity to any botulinum toxin preparations or to any component of the test article Current enrollment in an investigational drug or device trial or participation in such a trial within the last 30 days prior to screening through end of trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>glabellar lines, frown lines</keyword>
</DOC>